TABLE 2.
The efficacy of different groups
| Groups | PR (no. of patients with evaluable lesions) | SD (no. of patients with evaluable lesions), % | PD (no. of patients with evaluable lesions), % | PFS (months, 95% CI) (FAS) | OS (months, 95%CI) (FAS) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Osimertinib | Osimertinib plus antiangiogenic agents | Osimertinib | Osimertinib plus antiangiogenic agents | Osimertinib | Osimertinib plus antiangiogenic agents | ||||
| Group A (n = 12) | 4 (8), 50 | 0 (9), 0 | 4 (8), 50 | 9 (9), 100 | 0 (8), 0 | 0 (9), 0 | 21.0 (16.7–25.3) | 48.0 (NR) | |
| Group B (n = 30) | 9 (19), 47.4 | 3 (19), 15.8 | 8 (19), 42.1 | 13 (19), 68.4 | 2 (19), 22.2 | 3 (19), 15.8 | 9.2 (5.9–12.6) | 5.0* (4.5–5.5) | 31.8 (26.6–37.1) |
| Group C (n = 12) | / | 2 (5), 40 | / | 3 (5), 60 | / | 0 (5), 0 | 15.3 (7.9–22.7) | 28.5 (15.2–41.8) | |
Abbreviations: CI, confidence interval; FAS, full analysis set; NR, not reached; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease.
Note: *PFS2 of patients in Group B.